These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36992294)

  • 21. Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies.
    Guo H; Jiang J; Shen S; Ge X; Fan Q; Zhou B; Cheng L; Ju B; Zhang Z
    iScience; 2023 Apr; 26(4):106283. PubMed ID: 36925722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
    Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1.
    Davis-Gardner ME; Lai L; Wali B; Samaha H; Solis D; Lee M; Porter-Morrison A; Hentenaar IT; Yamamoto F; Godbole S; Douek DC; Lee FE; Rouphael N; Moreno A; Pinsky BA; Suthar MS
    bioRxiv; 2022 Nov; ():. PubMed ID: 36380757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies.
    Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O
    bioRxiv; 2022 Nov; ():. PubMed ID: 36415455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
    Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
    Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
    Hossain A; Akter S; Rashid AA; Khair S; Alam ASMRU
    Microb Pathog; 2022 Sep; 170():105699. PubMed ID: 35944840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility.
    Boer JC; Pan Q; Holien JK; Nguyen TB; Ascher DB; Plebanski M
    Front Immunol; 2022; 13():954435. PubMed ID: 36569921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.
    Jawad B; Adhikari P; Podgornik R; Ching WY
    Comput Biol Med; 2023 Dec; 167():107576. PubMed ID: 37871435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5.
    Molina KC; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    Int J Infect Dis; 2023 Jul; 132():34-39. PubMed ID: 37072054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid Identification of SARS-CoV-2 Omicron BA.5 Spike Mutation F486V in Clinical Specimens Using a High-Resolution Melting-Based Assay.
    Aoki A; Adachi H; Mori Y; Ito M; Sato K; Kinoshita M; Kuriki M; Okuda K; Sakakibara T; Okamoto Y; Jinno H
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection.
    Chen Z; Li J; Zheng J; Jin Y; Zhang Y; Tang F; Li J; Cheng H; Jiang L; Wen H; Hong C; Zeng X; Huang S; Lu B; Li L; Wang Z
    J Med Virol; 2023 Feb; 95(2):e28539. PubMed ID: 36719034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
    Cao Y; Song W; Wang L; Liu P; Yue C; Jian F; Yu Y; Yisimayi A; Wang P; Wang Y; Zhu Q; Deng J; Fu W; Yu L; Zhang N; Wang J; Xiao T; An R; Wang J; Liu L; Yang S; Niu X; Gu Q; Shao F; Hao X; Meng B; Gupta RK; Jin R; Wang Y; Xie XS; Wang X
    Cell Host Microbe; 2022 Nov; 30(11):1527-1539.e5. PubMed ID: 36270286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
    Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I;
    Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wastewater surveillance of SARS-CoV-2 variants in October-November 2022 in Italy: detection of XBB.1, BA.2.75 and rapid spread of the BQ.1 lineage.
    La Rosa G; Brandtner D; Bonanno Ferraro G; Veneri C; Mancini P; Iaconelli M; Lucentini L; Del Giudice C; Orlandi L; ; Suffredini E
    Sci Total Environ; 2023 May; 873():162339. PubMed ID: 36813191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 Spike Trimers: Balancing Stability and Adaptability in BA.1, BA.2 and BA.2.75 Variants.
    Verkhivker G; Alshahrani M; Gupta G
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
    Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
    Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.
    Wang Q; Li Z; Guo Y; Mellis IA; Iketani S; Liu M; Yu J; Valdez R; Lauring AS; Sheng Z; Gordon A; Liu L; Ho DD
    iScience; 2023 Nov; 26(11):108254. PubMed ID: 38026207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
    Xiang T; Wang J; Zheng X
    Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.